Targiniq is owned by Purdue Pharma Lp.

Targiniq contains Naloxone Hydrochloride; Oxycodone Hydrochloride.

Targiniq has a total of 15 drug patents out of which 9 drug patents have expired.

Expired drug patents of Targiniq are:

• US8969369
• US9161937
• US9345701
• US9084729
• US9283216
• US9056051
• US9283221
• US9168252
• US9511066

Targiniq was authorised for market use on 23 July, 2014.

Targiniq is available in tablet, extended release;oral dosage forms.

Targiniq can be used as management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate by providing an abuse-deterrent oral controlled release combination drug product, management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate.

The generics of Targiniq are possible to be released after 30 March, 2025.